Want to see IN:AKUMS full AI Analyst Report?
Top Page
Akums Drugs and Pharmaceuticals Limited
(AKUMS)
Select Model
Select Model
Rating:73Outperform
Price Target:
₹861.00
▲(25.80% Upside)
Action:Upgraded
Date:06/11/26
The score is driven primarily by improved financial strength (especially reduced leverage and stronger recent cash generation) alongside a constructive technical uptrend. These positives are partially offset by a higher valuation (P/E ~35.5) and the risk signaled by FY26 margin compression and earnings/cash-flow volatility.
Positive Factors
Revenue growth and earnings turnaround
Sustained revenue expansion and a return to profitability indicate improving operating scale and customer demand. As a CDMO serving multiple therapeutic areas and markets, this recovery can support durable growth if repeat client orders continue.
Negative Factors
Sharp margin compression
The steep FY26 margin decline signals pressure from costs, product mix or one-off items. If persistent, weaker per-unit economics could limit earnings growth even as revenue expands and reduce the benefit of Akums’ manufacturing scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and earnings turnaround
Sustained revenue expansion and a return to profitability indicate improving operating scale and customer demand. As a CDMO serving multiple therapeutic areas and markets, this recovery can support durable growth if repeat client orders continue.
Read all positive factors
Akums Drugs and Pharmaceuticals Limited (AKUMS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹122.26B
Dividend Yield0.38%
Average Volume (3M)16.32K
Price to Earnings (P/E)40.9
Beta (1Y)1.13
Revenue Growth9.18%
EPS Growth-14.57%
CountryIN
Employees7,337
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)12.42
Shares Outstanding157,393,980
10 Day Avg. Volume17,194
30 Day Avg. Volume16,317
Financial Highlights & Ratios
PEG Ratio-1.07
Price to Book (P/B)2.15
Price to Sales (P/S)1.64
P/FCF Ratio7.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)26.73
Revenue Forecast (FY)₹49.50B
Akums Drugs and Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Akums Drugs & Pharmaceuticals Ltd. is an Indian-based company, established in 2004 and headquartered in Delhi, that operates globally as a manufacturer and supplier of both finished pharmaceutical products and active pharmaceutical ingredients (AP...
How the Company Makes Money
AKUMS primarily makes money by providing contract manufacturing and related development services to pharmaceutical and healthcare companies. Its main revenue stream is the manufacture and sale of finished pharmaceutical products (finished dosage f...
Akums Drugs and Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
86
Very Positive
Cash Flow
72
Positive
| Breakdown | TTM | Mar 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.26B | 43.59B | 40.71B | 40.20B | 34.75B | 36.47B |
| Gross Profit | 7.62B | 9.37B | 16.05B | 14.37B | 11.67B | 12.69B |
| EBITDA | 2.39B | 6.31B | 5.29B | 1.31B | 3.09B | -821.80M |
| Net Income | 1.88B | 2.55B | 3.38B | -40.35M | 948.55M | -2.53B |
Balance Sheet | ||||||
| Total Assets | 51.59B | 54.47B | 41.13B | 35.16B | 32.67B | 30.69B |
| Cash, Cash Equivalents and Short-Term Investments | 16.78B | 16.81B | 5.82B | 2.88B | 1.50B | 1.03B |
| Total Debt | 902.87M | 1.57B | 882.12M | 5.65B | 6.19B | 3.95B |
| Total Liabilities | 19.91B | 21.16B | 10.50B | 27.96B | 25.43B | 24.44B |
| Stockholders Equity | 31.49B | 33.13B | 30.47B | 7.09B | 7.17B | 6.22B |
Cash Flow | ||||||
| Free Cash Flow | 13.13B | 9.80B | 1.93B | 1.87B | -1.52B | -2.26B |
| Operating Cash Flow | 15.47B | 12.11B | 4.65B | 4.98B | 1.77B | 318.54M |
| Investing Cash Flow | -12.71B | -9.69B | -5.48B | -3.30B | -3.05B | -2.35B |
| Financing Cash Flow | -5.29B | 430.11M | 727.88M | -1.08B | 1.25B | 2.36B |
Akums Drugs and Pharmaceuticals Limited Technical Analysis
Positive
684.40
Price Trends
689.39
Positive
615.94
Positive
532.68
Positive
Market Momentum
25.43
Negative
65.84
Neutral
74.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AKUMS, the sentiment is Positive. The current price of 684.4 is below the 20-day moving average (MA) of 737.46, below the 50-day MA of 689.39, and above the 200-day MA of 532.68, indicating a bullish trend. The MACD of 25.43 indicates Negative momentum. The RSI at 65.84 is Neutral, neither overbought nor oversold. The STOCH value of 74.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:AKUMS.
Akums Drugs and Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ₹172.38B | 29.39 | ― | 0.56% | 7.93% | 21.51% | |
73 Outperform | ₹122.26B | 40.90 | ― | 0.44% | 9.18% | -14.57% | |
61 Neutral | ₹94.44B | 15.39 | ― | 0.39% | 7.28% | 68.82% | |
57 Neutral | ₹185.81B | 58.53 | ― | 0.08% | 27.91% | 167.68% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹140.56B | 40.81 | ― | 0.52% | 16.27% | -23.50% |
* General Sector Average
IN:AKUMS
Akums Drugs and Pharmaceuticals Limited
779.00
308.28
65.49%
IN:ALIVUS
Glenmark Life Sciences Limited
1,443.55
512.78
55.09%
IN:JUBLPHARMA
Jubilant Pharmova Limited
908.45
-125.25
-12.12%
IN:SHILPAMED
Shilpa Medicare Limited
889.20
470.03
112.13%
IN:STAR
Strides Pharma Science Ltd
1,023.40
133.81
15.04%
IN:SUDEEPPHRM
Sudeep Pharma Limited
1,223.70
451.36
58.44%
Akums Drugs and Pharmaceuticals Limited Corporate Events
Akums to Acquire Oriflame India’s Manufacturing Assets for ₹56 Crore
Jul 23, 2026
Akums Drugs and Pharmaceuticals Limited has approved, via its wholly owned subsidiary Pure and Cure Healthcare, the acquisition of Oriflame India’s manufacturing business for INR 56 crore. The deal covers two plants in Roorkee and Noida, plu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.